Drug prices jump 5.7% in Q1; Hep C drugmakers scramble to cut weeks off treatment;

> Branded drug prices jumped 5.7% during the first quarter of 2015, with specialty meds increasing by 2.5%; the biggest increases came in infertility, menopause and hormone deficiency treatments, including generics. Release

> Hepatitis C drugmakers, including Gilead Sciences ($GILD), are racing to cut down on treatment times, hoping to gain an edge as new competitors hit the market. Report

> Generic drug use in Japan is on its way up, but not as much as expected, because consumers are loyal to their branded meds. Report

> MannKind ($MNKD) plans to manufacture a 12-unit cartridge strength of its inhaled insulin Afrezza, marketed by Sanofi ($SNY). Report

> A melanoma-fighting combo of Bristol-Myers Squibb's ($BMY) Yervoy and Opdivo caused one woman's tumor to "dissolve" so rapidly, it prompted a case study in the latest New England Journal of Medicine. Report

And Finally... BioDigital, which developed a "Google Earth" for the human body, won a 2015 Webby award; the company sees pharma companies as potential clients. Release

Suggested Articles

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.